Non-melanoma skin cancer (NMSC) is the most prevalent malignancy worldwide, with approximately 6.3 million new cases worldwide in 2019. One of the key management strategies for NMSC is a topical treatment usually utilised for localised and early-stage disease owing to its non-invasive nature. However, the efficacy of topical agents is often hindered by poor drug penetration and patient adherence. Therefore, various research groups have employed advanced drug delivery systems, including topical patches to overcome the problem of conventional topical treatments. This review begins with an overview of NMSC as well as the current landscape of topical treatments for NMSC, specifically focusing on the emerging technology of topical patches. A detailed discussion of their potential to overcome the limitations of existing therapies will then follow. Most importantly, to the best of our knowledge, this work unprecedentedly combines and discusses all the current advancements in innovative topical patches for the treatment of NMSC. In addition to this, the authors present our insights into the key considerations and emerging trends in the construction of these advanced topical patches. This review is meant for researchers and clinicians to consider utilising advanced topical patch systems in research and clinical trials toward localised interventions of NMSC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674480 | PMC |
http://dx.doi.org/10.3390/pharmaceutics15112577 | DOI Listing |
Contact Dermatitis
January 2025
Anna Belloni Fortina, University of Padua, Italy.
Background: Allergic contact dermatitis (ACD) induced by topical application of neomycin is frequently reported.
Objectives: This multi-center study investigated prevalence and determinants of neomycin sensitisations in 30 629 outpatients from North-eastern Italy during 1997-2021.
Patients And Methods: European baseline and extended Triveneto series were applied on the upper back of patients patch testing for suspected ACD and removed after 48 h.
Am J Case Rep
January 2025
Department of Pathology, Hospital Selayang, Batu Caves, Selangor, Malaysia.
BACKGROUND Primary cutaneous lymphomas (PCL) are a multifaceted spectrum of cutaneous T cell lymphoma (CTCL) and cutaneous B cell lymphomas (CBCL). Mycosis fungoides (MF) is a rare subset of CTCL that primarily affects adults, and its occurrence in children is exceedingly rare. Most pediatric MF manifests as hypopigmented patches resembling other benign dermatoses, causing diagnostic challenges.
View Article and Find Full Text PDFPharmaceutics
November 2024
Department of Pharmaceutics, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Center, 280 East Waihuan Road, Guangzhou 510006, China.
Indomethacin (IDM) is commonly used to treat chronic inflammatory diseases such as rheumatoid arthritis and osteoarthritis. However, long-term oral IDM treatment can harm the gastrointestinal tract. This study presents a design for encapsulating IDM within mixed micelles (MMs)-loaded dissolving microneedles (DMNs) to improve and sustain transdermal drug delivery.
View Article and Find Full Text PDFJ Anesth Analg Crit Care
January 2025
electroCore, Rockaway, NJ, USA.
Arch Dermatol Res
January 2025
Fixderma India Pvt Ltd, Sector 54, Gurgaon, 122011, Haryana, India.
Acanthosis Nigricans is characterised by hyperpigmented, hyperkeratotic, dark, rough patches or plaques distributed in intertriginous areas. Hyperkeratosis is the main concern that leads to the darkening of the skin. Numerous treatment options are available.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!